Nektar Therapeutics (NKTR) Market Cap & Valuation Ratios
Nektar Therapeutics (NKTR) has a market cap of $1.3B and a price-to-sales ratio of 23.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NKTRNektar TherapeuticsFollow NKTR — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| NKTR | 1.3 | — | 10.7 | — | — | -27% | -258% | -16% |
| INBX | 1.4 | — | — | — | -9.6% | — | — | — |
| ORIC | 1.4 | — | — | — | -8.2% | — | — | -53% |
| DMRA | 1.3 | — | — | — | -0.5% | — | — | — |
| TSHA | 1.3 | — | 161.2 | — | -10.3% | -32% | — | — |
| LBRX | 1.2 | — | — | — | -6.6% | — | — | -174% |
| RAPP | 1.2 | — | — | — | -7.8% | — | — | -54% |
| TYRA | 1.2 | — | — | — | -9.0% | — | — | -66% |
| OMER | 1.2 | — | — | — | -5.7% | — | — | -365% |
| SNDX | 1.2 | — | 3.5 | — | — | +223% | -77% | — |
| AVLN | 1.2 | — | — | — | — | — | — | — |
| Median of these 10 | — | 82.4 | — | -8.0% | +95% | -77% | -66% |
; EV/Sales 10.7 vs. 82.4.
Growth vs. price
each dot a company · hover or tap for valuesNektar Therapeutics — questions
- What is Nektar Therapeutics's market cap?
- $1.3B.
- What is Nektar Therapeutics's price-to-sales ratio?
- 23.3.
Every figure on this page comes from Nektar Therapeutics's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.